Published in Nat Rev Drug Discov on July 01, 2010
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84
Alzheimer mechanisms and therapeutic strategies. Cell (2012) 5.24
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. Cell (2011) 3.01
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology (2012) 2.66
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement (2014) 2.46
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov (2011) 1.71
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol (2010) 1.59
Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One (2012) 1.51
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Degeneration and repair in central nervous system disease. Nat Med (2010) 1.42
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement (2014) 1.28
Prediction of dementia in primary care patients. PLoS One (2011) 1.25
The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2013) 1.22
A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep (2014) 1.17
Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease. PLoS One (2011) 1.16
Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry (2011) 1.15
Biomarkers to predict antidepressant response. Curr Psychiatry Rep (2010) 1.14
Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine. J Transl Med (2012) 1.13
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov (2013) 1.12
The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest (2011) 1.11
Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One (2012) 1.09
Translating biomarkers to clinical practice. Mol Psychiatry (2011) 1.09
Retracted Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine. J Transl Med (2012) 1.08
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology (2013) 1.08
Functional biomarkers for neurodegenerative disorders based on the network paradigm. Prog Neurobiol (2011) 1.05
Hope builds for earlier detection of Alzheimer's disease. Nat Rev Drug Discov (2010) 1.05
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
Combining Multiple Markers to Improve the Longitudinal Rate of Progression-Application to Clinical Trials on the Early Stage of Alzheimer's Disease. Stat Biopharm Res (2013) 1.03
Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav (2012) 1.03
Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nat Med (2010) 1.01
Perspectives on episodic-like and episodic memory. Front Behav Neurosci (2013) 1.00
Imaging of glutamate neurotransmitter alterations in Alzheimer's disease. NMR Biomed (2012) 1.00
Cognitive intervention in Alzheimer disease. Nat Rev Neurol (2010) 0.99
Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol (2013) 0.98
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology (2016) 0.98
Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry (2014) 0.94
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Investigation of EEG abnormalities in the early stage of Parkinson's disease. Cogn Neurodyn (2013) 0.93
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias. Eur Arch Psychiatry Clin Neurosci (2012) 0.93
Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol (2011) 0.92
DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci (2014) 0.92
Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement (Amst) (2015) 0.90
Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making. J Digit Imaging (2013) 0.89
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther (2014) 0.89
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimers Dement (2013) 0.89
An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry (2013) 0.89
Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study. Exp Gerontol (2013) 0.89
Early intervention in Alzheimer's disease: a health economic study of the effects of diagnostic timing. BMC Neurol (2014) 0.89
Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med Genomics (2015) 0.89
Histologic validation of locus coeruleus MRI contrast in post-mortem tissue. Neuroimage (2015) 0.88
Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. Ann Clin Transl Neurol (2015) 0.88
Intra-membrane oligomerization and extra-membrane oligomerization of amyloid-β peptide are competing processes as a result of distinct patterns of motif interplay. J Biol Chem (2011) 0.87
Alzheimer disease and platelets: how's that relevant. Immun Ageing (2012) 0.87
BACE1 as a potential biomarker for Alzheimer's disease. J Alzheimers Dis (2011) 0.87
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging (2011) 0.86
Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Alzheimers Res Ther (2013) 0.85
Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Front Aging Neurosci (2014) 0.84
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer's disease subjects. Mol Neurodegener (2012) 0.84
Advances in tau-based drug discovery. Expert Opin Drug Discov (2011) 0.83
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry (2016) 0.82
A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer's disease. Neuroimage (2012) 0.82
Microbiosensor for Alzheimer's disease diagnostics: detection of amyloid beta biomarkers. J Neurochem (2012) 0.82
Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? Mol Cell Proteomics (2015) 0.82
Role of EEG as biomarker in the early detection and classification of dementia. ScientificWorldJournal (2014) 0.81
Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Front Aging Neurosci (2011) 0.81
Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer disease. J Neuropathol Exp Neurol (2013) 0.81
Will posttranslational modifications of brain proteins provide novel serological markers for dementias? Int J Alzheimers Dis (2012) 0.81
Platelets and Alzheimer's disease: Potential of APP as a biomarker. World J Psychiatry (2012) 0.81
The institutional review board is an impediment to human research: the result is more animal-based research. Philos Ethics Humanit Med (2011) 0.81
Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI. J Alzheimers Dis (2011) 0.80
Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention. Prog Neurobiol (2011) 0.80
Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol (2012) 0.80
Maximizing the value of diagnostics in Alzheimer's disease drug development. Nat Rev Drug Discov (2012) 0.80
Dementia in 2010: Paving the way for Alzheimer disease drug development. Nat Rev Neurol (2011) 0.79
Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis (2014) 0.79
Clusters of male and female Alzheimer's disease patients in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Brain Inform (2016) 0.79
Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology (2016) 0.79
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. J Prev Alzheimers Dis (2014) 0.78
Linking hypothetical knowledge patterns to disease molecular signatures for biomarker discovery in Alzheimer's disease. Genome Med (2014) 0.78
Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis (2011) 0.78
Magnesium protects cognitive functions and synaptic plasticity in streptozotocin-induced sporadic Alzheimer's model. PLoS One (2014) 0.78
Complexity of resting-state EEG activity in the patients with early-stage Parkinson's disease. Cogn Neurodyn (2016) 0.77
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J (2014) 0.77
Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer's Mice and in Human Patients. Curr Alzheimer Res (2015) 0.77
Genome-wide identification of microRNA-related variants associated with risk of Alzheimer's disease. Sci Rep (2016) 0.77
Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer's disease treatment. Int J Nanomedicine (2017) 0.77
Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimer's Disease in Mice, Observed by in Vivo Two-Photon Imaging. ACS Cent Sci (2016) 0.77
Divide and Conquer: Sub-Grouping of ASD Improves ASD Detection Based on Brain Morphometry. PLoS One (2016) 0.77
Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. Ann N Y Acad Sci (2015) 0.77
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol (2003) 16.17
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Forecasting the global burden of Alzheimer's disease. Alzheimers Dement (2007) 10.01
Surrogate end points in clinical trials: are we being misled? Ann Intern Med (1996) 9.81
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Alzheimer's disease. Lancet (2006) 9.15
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet (2008) 4.75
N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol (2007) 4.63
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
The FDA critical path initiative and its influence on new drug development. Annu Rev Med (2008) 4.08
Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A (2002) 4.07
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 3.99
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos Trans R Soc Lond B Biol Sci (2002) 3.74
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain (2007) 2.88
Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov (2003) 2.72
Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia (2008) 2.58
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res (1979) 2.41
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol (1998) 2.25
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Biomarkers and surrogate markers: an FDA perspective. NeuroRx (2004) 2.20
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx (2004) 2.02
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA (1999) 1.98
CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. Neurobiol Aging (2006) 1.96
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.89
1H magnetic resonance spectroscopy in dementia. Br J Radiol (2007) 1.87
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord (2005) 1.82
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 1.76
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry (2007) 1.68
The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer (2006) 1.67
Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord (1997) 1.62
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis (2007) 1.54
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging (2004) 1.48
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 1.48
Neurochemical aftermath of amateur boxing. Arch Neurol (2006) 1.47
Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics (2008) 1.46
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging (2001) 1.39
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Within-session and between-session reproducibility of cerebral sensorimotor activation: a test--retest effect evidenced with functional magnetic resonance imaging. J Cereb Blood Flow Metab (2001) 1.35
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res (2009) 1.34
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett (2000) 1.31
Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology (2005) 1.26
Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther (2004) 1.25
Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med (2007) 1.24
Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol (2005) 1.20
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther (2008) 1.16
Antecedent biomarkers of Alzheimer's disease: the adult children study. J Geriatr Psychiatry Neurol (2005) 1.16
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15
Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann Neurol (2004) 1.14
The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med (2004) 1.14
Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett (2002) 1.14
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Mild cognitive impairment. Lancet (2006) 10.21
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Alzheimer's disease. Lancet (2006) 9.15
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med (2008) 7.05
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Parkinson's disease. Lancet (2009) 6.60
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Burnout: a fashionable diagnosis. Dtsch Arztebl Int (2011) 4.64
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med (2010) 4.32
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med (2003) 4.20
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2007) 3.93
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 3.89
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol (2013) 3.70
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother (2009) 3.36
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov (2004) 2.96
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Developing the Sentinel System--a national resource for evidence development. N Engl J Med (2011) 2.93
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis (2013) 2.91
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem (2011) 2.82
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Developing the nation's biosimilars program. N Engl J Med (2011) 2.74
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol (2005) 2.65
Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain (2012) 2.65
Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J (2003) 2.64
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol (2010) 2.48
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
β-Propeller protein-associated neurodegeneration: a new X-linked dominant disorder with brain iron accumulation. Brain (2013) 2.40
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry (2006) 2.39